Transient exposure to inflammation-associated, fibroblast-stimulatory factors appears to initiate fibrosis by inducing the persistently activated phenotypes displayed by fibroblast cultures derived from scleroderma skin and other fibrotic tissues. To determine whether one class of fibroblast-inhibitory factors, the interferons (IFNs), plays a role in terminating fibrosis by acting as persistent fibroblast deactivators, we inhibited (40-60%) the growth and collagen production of normal dermal fibroblasts and hypercollagen-producing scleroderma fibroblasts by shortterm exposure to IFN-a, ft, or Sy. During subsequent subculture in the absence of IFNs, the growth and collagen production of normal fibroblasts and the growth of scleroderma fibroblasts increased to untreated control levels after two to three passages. In contrast, collagen production by scleroderma fibroblasts remained inhibited for at least five passages (18 cell doublings) and was not further suppressed by subsequent IFN exposure. These data suggest that IFNs may help terminate fibrosis by suppressing persistently activated fibroblast functions.
Introduction
Fibroblasts are responsible for the production and maintenance of the connective-tissue matrix. Under basal conditions, the growth and synthetic activities of resident fibroblasts are of a limited nature and likely controlled only by interaction with native connective-tissue matrix components (1, 2) . However, after either traumatic or pathological tissue injury, resident fibroblasts undergo a metabolic activation and exhibit the increased growth and synthetic rates required to effect the fibrotic repair of injured tissue. This fibroblast activation is believed to be controlled by the presence of numerous stimulatory factors released into the tissue fluid environment as a result of blood vessel disruption and the infiltration and activation of platelets, neutrophils, monocytes/macrophages, and T lymphocytes during the inflammation and granulation tissue phases of the fibrotic response (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) .
Whereas fibrosis in response to traumatic injury is usually a transient process resulting in healed wounds with minimal scar formation, pathological fibrosis is often a persistent chronic process resulting in excessive tissue scarring. Cultured fibroblasts derived from sites of pathological fibrosis, such as rheumatoid synovium, and keloid or scleroderma skin, display activated phenotypes characterized by increased production of the connective-tissue matrix components: collagens (17-23), glycosaminoglycans (17, 24), and fibronectin (21) , as well as altered growth (17) and collagenase (18, 25) and prostaglandin E2 production (25) . Moreover, a portion of these cultured fibroblasts, activated by the in vivo environment from which they were excised, appear to be permanently, or at least persistently, activated as their hyperactive phenotypes persist through numerous subcultures in vitro (17) (18) (19) (20) (22) (23) (24) (25) .
Studies investigating the environmental stimulatory factors responsible for inducing pathologic fibroblast activation have recently focused on those produced by mononuclear cells, because it has long been recognized that both T lymphocytes and monocytes/macrophages are present during the inflammatory phase of pathological fibrosis (26) (27) (28) (29) . These studies indicate that both T lymphocyte-derived lymphokines (15, 16, 29, 30) and monocyte/macrophage-derived monokines (12) (13) (14) (30) (31) (32) (33) can stimulate normal fibroblast functions in vitro. Further, in two instances, namely, glycosaminoglycan and prostaglandin E2 production, it has been demonstrated that the stimulated phenotypes induced by culture in lymphokine/monokine supernatants are retained in the absence ofthe stimulating agents and that the induced activated phenotypes persist throughout numerous cell doublings and subcultures (34, 35) .
Mononuclear cell-derived factors may also play a role in moderating or in terminating the fibrotic response as lymphokines and monokines inhibiting the functions of both normal and activated fibroblasts have also been described (16, 23, (36) (37) (38) . We and others have been recently identified those inhibiting fibroblast growth and collagen production as monocyte-derived interferon (IFN)1-a/,3 and T lymphocyte-derived IFN-y (39) (40) (41) IFN treatment and subculture. Subconfluent fibroblast cultures were set up by placing 10,000 freshly trypsinized fibroblasts, contained in I ml of DME-20% FCS, into triplicate 2-cm2 wells and incubating for 18 h at 37°C in a 5% CO2 atmosphere to permit adherence to well bottoms. After adherence, medium was removed and replaced with 1 ml of fresh DME-20% FCS with or without 1,000 U/ml of either IFN-a2, ,, or 'y, and cultures incubated for an additional 96 h. After 96 h of growth, fibroblasts were trypsinized, washed, and subcultured at 10,000 cells per 2-cm2 well in the absence of IFNs. These subcultures were maintained without media changes and subsequently passaged every 7 d for an additional 4 wk during which time both untreated normal and untreated scleroderma fibroblasts underwent an average of 18 cell doublings. The growth and collagen production of untreated control and IFN-treated fibroblasts were assessed at each subculture as described below. After the last passage, fibroblasts were again tested for sensitivity to IFN treatment by incubation with 1,000 U/ml of IFN-a2, fl, or y.
Assay offibroblast growth. Assay of FCS-driven fibroblast growth was performed using asynchronous nonconfluent fibroblast cultures seeded at 10,000 cells per 2-cm2 well as described above. Because FCSdriven fibroblast growth is caused by the orchestrated action of the numerous peptide growth factors contained in serum, we performed all the studies reported herein using the same lot of FCS in order to eliminate lot-to-lot variation in these peptide growth factors. After 96 h of culture in DME-20% FCS with or without IFNs, growth was assessed by counting the number of trypsin-released cells present using a hemocytometer. Assays were done using triplicate cultures and each culture was counted twice and values are expressed as the number of cells per 2-cm2 well. broblasts (44) and may partially mimic the in vivo environment to which scleroderma fibroblasts are exposed during the edematous and scleroedematous stages of the disease, inasmuch as the microvascular endothelial cell damage and platelet activation associated with scleroderma would likely expose in situ scleroderma fibroblasts to the same growth and collagen-production stimulatory factors present in FCS (45) . A single lot ofFCS was used for all studies in order to eliminate variability owing to factors contained in FCS, such as transforming growth factor-a, which have collagen-production stimulatory activity (9, 30) . In order to maximize the differences between normal and scleroderma fibroblast colagen production, we employed a suboptimal feeding schedule similar to those previously described (20, 23, 41) , although otherstudies show that optimal feeding schedules will also reveal the hypercollagen-producing phenotype of scleroderma fibroblasts (22) .
Fibroblasts grown to confluency after 7 d of culture without media changes were trypsinized and plated in triplicate in 96-well microcultures (Microtest III, Falcon Labware, Oxnard, CA) at a near-confluent density of 25,000 fibroblasts per well in 100 Ml of DME-20% FCS and incubated for 48 h to produce a totally confluent monolayer of fibroblasts. The medium was then removed and replaced with 200 JA of DME plus 10% FCS containing 50 M&g/mI ascorbic acid with or without IFNs, and incubated for an additional 48 h. Cultures were labeled with 0.5 MCi of [3H]proline incorporation into pepsin-resistant, salt-precipitated extracellular collagen was then determined as previously described (37, 39, 46) . In our hands this assay yields material that is 95% collagenase-digestible, and the method isolates < 1% of noncollagenous proteins biosynthetically labeled with [3H]tryptophan (39 
Results
Growth and collagen production ofuntreated controlfibroblasts.
The study was initiated with fibroblast lines in both the second and ninth passages. As shown in Table I , growth rates of both normal and scleroderma lines at the initiation ofthe study without IFN treatment covered a two-to threefold range, but the average growth of the nine untreated normal and five untreated scleroderma lines (both in-house and ATCC-derived) was similar to that of 10,000 seeded cells expanding to -100,000 cells over 4 d of growth as has previously been noted (19, 20, 22) . During the 3 1-d, five-subculture course of the study, the growth rate of these untreated normal and scleroderma lines remained virtually constant with cells initiated in both the second and ninth passages (see Tables III and IV) . The collagen production of individual normal and scleroderma lines at the initiation of the study also varied over a twoto threefold range as illustrated in Table II . However, both inhouse and ATCC-derived scleroderma lines exhibited an elevated collagen production, and the average collagen production ofthe five untreated scleroderma lines was 69% greater than the untreated normal cells, suggesting they possessed an activated collagen producing-phenotype as has previously been demonstrated in other studies (19) (20) (21) (22) (23) . The collagen production of the untreated normal and scleroderma lines studied remained virtually constant over the 31 d ofthe study with the average scleroderma fibroblast collagen production remaining significantly greater than normal fibroblast production for the entire period, regardless ofwhether cultures were initiated in the second or ninth passage (see Tables V and VI) .
Effect ofshort-term IFN treatment on fibroblast growth. To determine the effect of short-term IFN treatment on fibroblast growth and collagen production, fibroblasts were treated for 4 d with 1,000 U/ml of IFN-a2, ,, or y, and then the growth and collagen production of the fibroblasts subcultured in the absence of IFNs was followed for an additional five passages over 31 d as described in the Methods.
The mean effect of IFN treatment on the growth of nine normal fibroblast lines is shown in Table III . On day 0, after 4 d of treatment with 1,000 U/ml of either rIFN-a2, nIFN-P, or rIFN-'y, cell growth was inhibited by 50-60% as we and others have previously reported (39, 47) . However, after three subcultures (-10 cell doublings) in the absence of IFNs, cell growth returned to untreated control levels. The growth of the five scleroderma fibroblast lines was similarly inhibited by 4 d of treatment with all IFNs as shown in Table IV . Similar to normal fibroblasts, the IFN inhibition of scleroderma fibroblast growth was also a transient effect, with all growth returning to untreated control levels after only three subcultures in the absence of IFNs.
Effect of short-term IFN treatment on fibroblast collagen production. The effect of IFN treatment on the collagen production of normal fibroblasts, shown in Table V, illustrates that on day 0 after 4 d of treatment, all three IFNs caused collagen production to be inhibited by 50-60% as we have previously reported (39) . Once again, however, the IFN inhibition was only a transient effect, because collagen production returned to untreated control levels after two to three subcultures without IFNs.
In contrast, 4 d of treatment with all three IFNs not only initially inhibited the collagen production of scleroderma fibro- blast on day 0 by 50-60% but the collagen production of these cells, although rising somewhat through the first two passages, remained markedly reduced throughout the entire 3 l-d, 18 -cell division, subculture period in the absence of IFNs (Table VI) . Moreover, the reduced amount of collagen produced by these inhibited cells was now approximately equal to that produced by untreated normal fibroblasts. These data suggest IFNs have persistently reduced the collagen-producing phenotype of these scleroderma-derived fibroblasts.
Response of31-d posttreatment fibroblasts to reexposure to IFNs. To determine whether these reduced-phenotype fibroblasts now behave as normal fibroblasts by responding to IFNs with a transient further reduction of collagen production, we reexposed 3 1-d posttreatment fibroblasts to the IFNs with which they had originally been treated. However, scleroderma fibroblast collagen production was now largely unresponsive to IFN treatment and was not markedly inhibited (Table VII) . This was in contrast to the significant reinhibition of the growth of scleroderma fibro- Hu-rIFN-y
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Subconfluent cultures of nine normal and five scleroderma fibroblast lines were treated with IFNs (1,000 U/ml) for 96 h and then subcultured in the absence of IFNs for five passages over 28 d. Cultures of these fibroblasts, set up as described in Methods for assays of fibroblast growth or collagen production, were assayed for growth or collagen production on day 31 after incubation in the absence or presence of 1,000 U/ml of the IFNs to which they had originally been exposed. * Values are statistically different from controls not reexposed to IFNs (P < 0.05 by two-tailed t test).
blasts and the growth and collagen production of normal fibroblasts. Thus, although IFN-treated scleroderma fibroblasts produce normal amounts of collagen, they do not seem to possess all the characteristics of normal fibroblasts inasmuch as their collagen production could not be reinhibited by subsequent IFN treatment.
Discussion
Because we had recently identified IFN--y as the lymphokine and IFN-a and , as the monokines responsible for inhibiting fibroblast growth and collagen production, in this report we investigated whether IFNs could persistently normalize the activity of cultured fibroblast previously activated in vivo. We chose fibroblasts derived from scleroderma skin as our activated model because they display persistently activated phenotypes characterized by the hyperproduction of collagens, fibronectin, and glycosaminoglycans but normal growth and collagenase production rates (19) (20) (21) (22) (23) (24) . In this way we could study the effect of IFNs on both activated (collagen production) and normal (growth) functions in the same fibroblast line. Moreover, similar transcription-regulatory mechanisms may be responsible for the increased collagen production of scleroderma fibroblasts and the decreased collagen production ofIFN-treated fibroblasts, inasmuch as scleroderma fibroblasts have increased levels of procollagen messenger RNA (mRNA), and IFN treatment decreases the procollagen mRNA levels of both scleroderma and normal fibroblasts (41, 48, 49) .
The results of our study demonstrate that both scleroderma and normal fibroblasts are sensitive to the initial inhibitory effects of either IFN-a, ,, or y, inasmuch as the growth and collagen production of both fibroblast types were inhibited 40-60% by 96 h of IFN treatment. However, those fibroblast functions that were normally active, namely, the growth and collagen production of normal fibroblasts and the growth of scleroderma fibroblasts, returned to untreated levels during subsequent subculture in the absence of IFNs. In contrast, scleroderma fibroblast collagen production, an activated function, remained inhibited for 18 cell doublings in the absence of IFNs. This population of deactivated scleroderma fibroblasts, although producing normal amounts of collagen, was however, not identical to the normal unactivated fibroblast populations studied because its collagen production was no longer sensitive to IFN-mediated inhibition. These data suggest, that although IFNs are only transient inhibitors of normal fibroblast functions, they do indeed act as persistent deactivators of at least one activated fibroblast function. Whether IFNs inhibit other activated fibroblast functions such as glycosaminoglycan or fibronectin production in a persistent manner remains to be investigated. However, IFN-y has been reported to inhibit both the collagen and fibronectin production of rheumatoid synovial fibroblast-like cells, although persistence of inhibition was not investigated (50) .
In the present study, we have not attempted to analyze the types of collagens produced before and after IFN treatment nor the mechanism by which IFNs inhibit collagen production.
However, previous reports demonstrate that in the presence of FCS both normal and scleroderma fibroblasts produce type I and III collagen in a ratio of -5:1 (22) , and short-term IFN treatment causes a coordinate decrease in the production ofboth type I and III collagen in normal and scleroderma fibroblasts as assessed by procollagen and procollagen mRNA levels (40, 41, 49) . The IFN-induced decreases in procollagen mRNAs were proportionate to procollagen reduction and no detectable increase of collagen degradation products was observed, suggesting that IFNs act at a transcriptional level (40, 41, 49) . Whether IFNs inhibit only the procollagen mRNA synthesis induced by the transforming growth factor-,B contained in FCS-supplemented media (9, 39), or also inhibit basal level procollagen mRNA synthesis was not assessed. However, we have previously shown that IFNs or mononuclear cell supernatants containing IFNs can inhibit both normal and scleroderma fibroblast collagen production in cultures containing low (1%) or no FCS (37, 39, unpublished observations).
The mechanism responsible for the observed emergence of a persistently reduced collagen-producing phenotype after transient exposure of scleroderma fibroblasts to IFNs may involve either clonal selection or phenotype differentiation. Because the activated scleroderma fibroblasts that we studied were growing when treated with IFNs, it is possible that the deactivation of collagen production that we observed was due to clonal selection inasmuch as the IFNs were also growth inhibitors. Moreover, the collagen production ofthe deactivated scleroderma fibroblast was insensitive to subsequent IFN Having demonstrated that IFNs deactivate scleroderma fibroblasts it is logical for us to suggest that the excessive fibrosis seen in vivo in scleroderma may be due to the deficient in situ production of IFNs by infiltrating monocytes/macrophages and T lymphocytes during the early edematous and scleroedematous stages of disease (26) (27) (28) (29) . This, however, may not be the case, because peripheral blood mononuclear cells from scleroderma patients produce normal amounts of collagen production-inhibitory factors now known to be IFNs (23, 37) . Production of excessive amounts of a collagen production-stimulatory lymphokine by scleroderma peripheral blood mononuclear cells has, however, been reported (52) , and this factor may be responsible for in vivo activation of hypercollagen-producing fibroblasts. Nevertheless, our results suggest that scleroderma may be amenable to therapy with IFNs or IFN inducers in that increasing in vivo levels of IFN would likely block the effect of excessive stimulatory factors, resulting in fibroblast deactivation. Similarly, other diseases characterized by pathological fibrosis, such as forms ofpulmonary and liver fibrosis, chronic graft-vs.-host disease, rheumatoid arthritis, localized scleroderma, keloids, and hypertrophic scars, may also benefit from IFN treatment, regardless of the mechanisms leading to aberrant fibroblast activation. This concept of general in vivo fibroblast deactivation by IFNs is supported by a recently reported study showing that in vivo administration of IFN-'y prevents accumulation of collagen in the lungs of bleomycin-treated mice (53) and by reports of delayed wound healing in viral infected mice that may be due to the presence of high levels of virally induced IFN (54) .
